LON:AREC Arecor Therapeutics (AREC) Share Price, News & Analysis → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free AREC Stock Alerts GBX 132.50 0.00 (0.00%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range 130▼ 13550-Day Range 128.50▼ 156.5052-Week Range 125▼ 280Volume10,876 shsAverage Volume12,530 shsMarket Capitalization£40.58 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsHeadlinesStock AnalysisChartCompetitorsHeadlines Get Arecor Therapeutics alerts: Email Address Ad Stansberry ResearchThe "Smart Money" Is Ready for May 1st Are You?Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company. One Former Wall St. Trader Explains Why… About Arecor Therapeutics Stock (LON:AREC)Arecor Therapeutics plc, a biopharmaceutical company, focuses on developing products in diabetes and other indications. The company through its proprietary formulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of therapeutic products. It also offers Ogluo, a ready-to-use glucagon auto-injector pen that is used to treat hypoglycaemia in patients with diabetes; and specialty hospital care products. In addition, the company is developing AT247, an ultra-rapid acting insulin for patients with Type I and Type II diabetics; and AT278, an ultra-concentrated rapid acting insulin formulation that has been designed to accelerate the absorption of insulin post injection. It has a research collaboration with TRx Biosciences Limited for the formulation development of an oral glucagon-like peptide-1 (GLP-1) receptor agonist product. The company was founded in 2007 and is headquartered in Little Chesterford, the United Kingdom.Read More AREC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AREC Stock News HeadlinesApril 23, 2024 | lse.co.ukArecor chief financial officer to leave in July after five yearsApril 18, 2024 | morningstar.comArecor Therapeutics PLC Ordinary Shares ARECApril 24, 2024 | Stansberry Research (Ad)How to camouflage a factory of 53,000 workers"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."April 2, 2024 | lse.co.ukStrip Tinning shares up as hails "largest ever" glazing orderMarch 14, 2024 | finance.yahoo.comArecor Therapeutics announces collaboration on oral GLP-1 drug for diabetes and obesity treatmentMarch 12, 2024 | lse.co.ukArecor to develop "holy grail" diabetes treatment with partner TRxMarch 12, 2024 | finance.yahoo.comARECOR AND TRx BIOSCIENCES ESTABLISH RESEARCH COLLABORATION TO DEVELOP ORAL GLP-1 WITH ENHANCED BIOAVAILABILITYFebruary 16, 2024 | finance.yahoo.comArecor Therapeutics plc (AREC.L)April 24, 2024 | Stansberry Research (Ad)How to camouflage a factory of 53,000 workers"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."February 1, 2024 | lse.co.ukArecor Therapeutics hails Arestat as 2023 performance "strong"January 20, 2024 | morningstar.comArecor Therapeutics PLC Ordinary SharesJanuary 18, 2024 | lse.co.ukTRADING UPDATES: Patent boosts for DG Innovate and Arecor TherapeuticsDecember 4, 2023 | lse.co.ukArecor inks co-development deal with global medical companyNovember 17, 2023 | finance.yahoo.comArecor Therapeutics takes major step with first commercial sale of AT220November 2, 2023 | lse.co.ukTRADING UPDATES: Troy Income suspends buyback of sharesSeptember 4, 2023 | lse.co.ukArecor Therapeutics subsidiary Tetris Pharma signs deal with GoodlifeAugust 17, 2023 | lse.co.ukArecor Therapeutics to collaborate with "top 10" pharmaceutical firmJuly 20, 2023 | marketwatch.comArecor Therapeutics Flags Strong 1H ProgressJuly 20, 2023 | finance.yahoo.comArecor: Business UpdateJune 3, 2023 | finance.yahoo.comShareholders in Arecor Therapeutics (LON:AREC) are in the red if they invested a year agoApril 24, 2023 | finance.yahoo.comArecor Therapeutics has "a strong basis to accelerate" growth strategyMarch 14, 2023 | finance.yahoo.comRecent uptick might appease Arecor Therapeutics plc (LON:AREC) institutional owners after losing 16% over the past yearDecember 1, 2022 | msn.comArecor to launch second Phase I clinical trial of AT278 rapid-acting insulin for diabetes patientNovember 10, 2022 | finance.yahoo.comEven after rising 12% this past week, Arecor Therapeutics (LON:AREC) shareholders are still down 43% over the past yearNovember 1, 2022 | finance.yahoo.comTetris Pharma Launches Ogluo® in GermanyOctober 11, 2022 | finance.yahoo.comHeadline results from Phase I clinical trial of ultra-rapid acting insulin candidate AT247 demonstrate significantly accelerated insulin absorption and early exposure compared to gold standard insulins NovoLog® and Fiasp®August 24, 2022 | investing.comArecor Therapeutics PLC (AREC)See More Headlines Receive AREC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arecor Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:AREC CUSIPN/A CIKN/A Webwww.americanresourcescorp.com Phone44 1223 426 060FaxN/AEmployees51Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-9,420,000.00 Net Margins-278.81% Pretax MarginN/A Return on Equity-67.81% Return on Assets-34.01% Debt Debt-to-Equity Ratio1.26 Current Ratio2.52 Quick Ratio6.24 Sales & Book Value Annual Sales£3.38 million Price / Sales12.01 Cash FlowGBX 26.13 per share Price / Cash Flow5.07 Book ValueGBX 43 per share Price / Book3.08Miscellaneous Outstanding Shares30,630,000Free FloatN/AMarket Cap£40.58 million OptionableNot Optionable Beta-0.22 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Sarah Jennifer Howell Ph.D. (Age 49)CEO & Director Comp: $421kMs. Susan Day Lowther FCMA (Age 64)CFO, Company Secretary & Director Comp: $306kDr. Jan Jezek Ph.D.Chief Scientific OfficerMr. David GerringSenior Vice President of DevelopmentDr. Manjit Rahelu Ph.D.Chief Business OfficerKey CompetitorsRedx PharmaLON:REDXTissue Regenix GroupLON:TRXBiodexa PharmaceuticalsLON:MTPHCollagen Solutions plc (COS.L)LON:COS4D pharmaLON:DDDDView All Competitors AREC Stock Analysis - Frequently Asked Questions How have AREC shares performed in 2024? Arecor Therapeutics' stock was trading at GBX 182.50 at the beginning of 2024. Since then, AREC shares have decreased by 27.4% and is now trading at GBX 132.50. View the best growth stocks for 2024 here. How do I buy shares of Arecor Therapeutics? Shares of AREC stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:AREC) was last updated on 4/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencySHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingMan Who Predicted 2008: “This Will be Worse.”AltimetryBiden out June 13; Kamala won’t replace him?Paradigm PressNew Trump BombshellThe Freeport SocietyThe Greatest Bull Market in Crypto History…Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arecor Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
